Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that ...
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential ...
Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update)
Vigil Neuroscience (VIGL) stock rises as the Sanofi (SNY)-backed biotech plans to advance its Alzheimer's candidate VG-3927 into a Phase 2 trial in Q3. Read more here.
Yahoo Finance6d
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment ...
Vigil Neuroscience’s VG-3927: Promising Phase 1 Results and Strategic Positioning for Phase 2
Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated ...
Vigil Neuroscience’s (VIGL) Buy Rating Reiterated at Guggenheim
Guggenheim reissued their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a report issued on Friday ...
Vigil Neuroscience’s (VIGL) “Buy” Rating Reiterated at HC Wainwright
Vigil Neuroscience (NASDAQ:VIGL – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on ...
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential ...
Mena FN6d
Vigil Neuroscience To Present At Guggenheim Securities SMID Cap Biotech Conference
(MENAFN- GlobeNewsWire - Nasdaq) WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company ...